ImmunityBio, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
21.23 |
100.88 |
242.39 |
879.46 |
1,780.06 |
3,394.52 |
| Przychód Δ r/r |
0.00% |
375.28% |
140.28% |
262.82% |
102.40% |
90.70% |
| Przychód (min) |
20.79 |
92.16 |
155.78 |
677.50 |
1,371.29 |
2,615.01 |
| Przychód (max) |
21.66 |
109.60 |
302.64 |
1,055.82 |
2,137.02 |
4,075.23 |
| EBITDA (średnia) |
-21.23 |
-100.88 |
-242.39 |
-879.46 |
-1,780.06 |
-3,394.52 |
| EBIT (średnia) |
-21.23 |
-100.88 |
-242.39 |
-879.46 |
-1,780.06 |
-3,394.52 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-557.31 |
-323.60 |
-222.39 |
100.29 |
560.35 |
1,306.33 |
| Zysk netto % |
-2625.71% |
-320.79% |
-91.75% |
11.40% |
31.48% |
38.48% |
| EPS (średnia) |
-0.80 |
-0.46 |
-0.32 |
0.18 |
0.80 |
1.86 |
| Liczba analityków (Przychody) |
3 |
3 |
4 |
2 |
1 |
1 |
| Liczba analityków (EPS) |
2 |
2 |
3 |
3 |
1 |
1 |
| symbol |
IBRX |
IBRX |
IBRX |
IBRX |
IBRX |
IBRX |